http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 14 Aug 2026 18:38:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++GH+Research+PLC++++++++++++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./26933147.html si-local-file:///var/storage/secattach/20260814/26933147.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++GH+Research+PLC++++++++++++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./26933147.html Fri, 14 Aug 2026 18:38:00 -0400 GHRS O.50288575 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++GH+Research+PLC++++++++++++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./26933147.html si-local-file:///var/storage/secattach/20260814/26933147.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++GH+Research+PLC++++++++++++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./26933147.html Fri, 14 Aug 2026 18:38:00 -0400 GHRS O.50288575 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++GH+Research+PLC++++++++++++++++++++++++Filed+by%3A+Lynx1+Capital+Management+LP/26931688.html si-local-file:///var/storage/secattach/20260814/26931688.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++GH+Research+PLC++++++++++++++++++++++++Filed+by%3A+Lynx1+Capital+Management+LP/26931688.html Fri, 14 Aug 2026 16:37:00 -0400 GHRS O.50288575 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++GH+Research+PLC++++++++++++++++++++++++Filed+by%3A+Lynx1+Capital+Management+LP/26931688.html si-local-file:///var/storage/secattach/20260814/26931688.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++GH+Research+PLC++++++++++++++++++++++++Filed+by%3A+Lynx1+Capital+Management+LP/26931688.html Fri, 14 Aug 2026 16:37:00 -0400 GHRS O.50288575 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GH+Research+PLC+++++++++++For%3A+Aug+11++Filed+by%3A+Moore+Duncan/26922462.html si-local-file:///var/storage/secattach/20260813/26922462.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GH+Research+PLC+++++++++++For%3A+Aug+11++Filed+by%3A+Moore+Duncan/26922462.html Thu, 13 Aug 2026 17:00:00 -0400 GHRS O.50288575 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GH+Research+PLC+++++++++++For%3A+Aug+11++Filed+by%3A+Moore+Duncan/26922462.html si-local-file:///var/storage/secattach/20260813/26922462.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GH+Research+PLC+++++++++++For%3A+Aug+11++Filed+by%3A+Moore+Duncan/26922462.html Thu, 13 Aug 2026 17:00:00 -0400 GHRS O.50288575 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GH+Research+PLC+++++++++++For%3A+Aug+11++Filed+by%3A+Hanley+Dermot+John/26922310.html si-local-file:///var/storage/secattach/20260813/26922310.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GH+Research+PLC+++++++++++For%3A+Aug+11++Filed+by%3A+Hanley+Dermot+John/26922310.html Thu, 13 Aug 2026 16:46:00 -0400 GHRS O.50288575 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GH+Research+PLC+++++++++++For%3A+Aug+11++Filed+by%3A+Hanley+Dermot+John/26922310.html si-local-file:///var/storage/secattach/20260813/26922310.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GH+Research+PLC+++++++++++For%3A+Aug+11++Filed+by%3A+Hanley+Dermot+John/26922310.html Thu, 13 Aug 2026 16:46:00 -0400 GHRS O.50288575 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GH+Research+PLC+++++++++++For%3A+Aug+11++Filed+by%3A+Forer+Michael/26922210.html si-local-file:///var/storage/secattach/20260813/26922210.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GH+Research+PLC+++++++++++For%3A+Aug+11++Filed+by%3A+Forer+Michael/26922210.html Thu, 13 Aug 2026 16:43:00 -0400 GHRS O.50288575 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GH+Research+PLC+++++++++++For%3A+Aug+11++Filed+by%3A+Forer+Michael/26922210.html si-local-file:///var/storage/secattach/20260813/26922210.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GH+Research+PLC+++++++++++For%3A+Aug+11++Filed+by%3A+Forer+Michael/26922210.html Thu, 13 Aug 2026 16:43:00 -0400 GHRS O.50288575 http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+GH+Research+PLC+%28GHRS%29/26893876.html <p>H.C. Wainwright analyst Patrick R. Trucchio reiterated a Buy rating and $65.00 price target on GH Research PLC (NASDAQ: GHRS).</p><p>The analyst commented: "On August 6, GH Research reported 2Q26 results in which GH announced the receipt of a written FDA response from July 2026 confirming that its chemistry, manufacturing and controls (CMC) and device plans appear Phase 3 ready. Additionally, both bridging Phase 1 trials are complete — GH001-HV-106, the clinical pharmacology trial evaluating the proprietary aerosol delivery device, and GH001-HV-109, the U.S. Investigational New Drug (IND)-opening healthy volunteer trial — and pivotal doses have been selected on the basis http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+GH+Research+PLC+%28GHRS%29/26893876.html Mon, 10 Aug 2026 06:44:01 -0400 GHRS http://www.streetinsider.com/Earnings/GH+Research+PLC+%28GHRS%29+Tops+Q2+EPS+by+9c/26879281.html <p>GH Research PLC (NASDAQ: GHRS) reported Q2 EPS of ($0.23), $0.09 better than the analyst estimate of ($0.32).</p><p>For earnings history and earnings-related data on GH Research PLC (GHRS) <a href="http://www.streetinsider.com/ec_earnings.php?q=GHRS">click here</a>.</p> http://www.streetinsider.com/Earnings/GH+Research+PLC+%28GHRS%29+Tops+Q2+EPS+by+9c/26879281.html Thu, 06 Aug 2026 08:01:21 -0400 GHRS http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GH+Research+PLC+++++++++++For%3A+Jun+30/26878745.html si-local-file:///var/storage/secattach/20260806/26878745.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GH+Research+PLC+++++++++++For%3A+Jun+30/26878745.html Thu, 06 Aug 2026 07:25:00 -0400 GHRS O.50288575 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GH+Research+PLC+++++++++++For%3A+Jun+30/26878745.html si-local-file:///var/storage/secattach/20260806/26878745.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++GH+Research+PLC+++++++++++For%3A+Jun+30/26878745.html Thu, 06 Aug 2026 07:25:00 -0400 GHRS O.50288575 http://www.streetinsider.com/Press+Releases/GH+Research+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878306.html <ul type="disc"><li>Alignment with FDA on CMC and device plans for Phase 3</li><li>Successfully completed GH001-HV-106 and GH001-HV-109 Phase 1 trials </li><li>Further strengthening of US and EU mebufotenin patent estate</li><li>Phase 2a results in postpartum depression published in <em>The Journal of Clinical Psychiatry</em></li><li>Cash, cash equivalents and marketable securities of $362.7 million as of June 30, 2026</li></ul> <p align="justify">DUBLIN, Aug. 06, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended June 30, 2026, and provided a http://www.streetinsider.com/Press+Releases/GH+Research+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878306.html Thu, 06 Aug 2026 07:00:00 -0400 A.01908724 A.03718595 GHRS O.04906507 O.20988509 O.50288575 http://www.streetinsider.com/Press+Releases/GH+Research+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878306.html <ul type="disc"><li>Alignment with FDA on CMC and device plans for Phase 3</li><li>Successfully completed GH001-HV-106 and GH001-HV-109 Phase 1 trials </li><li>Further strengthening of US and EU mebufotenin patent estate</li><li>Phase 2a results in postpartum depression published in <em>The Journal of Clinical Psychiatry</em></li><li>Cash, cash equivalents and marketable securities of $362.7 million as of June 30, 2026</li></ul> <p align="justify">DUBLIN, Aug. 06, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended June 30, 2026, and provided a http://www.streetinsider.com/Press+Releases/GH+Research+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878306.html Thu, 06 Aug 2026 07:00:00 -0400 A.01908724 A.03718595 GHRS O.04906507 O.20988509 O.50288575 http://www.streetinsider.com/Press+Releases/GH+Research+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878306.html <ul type="disc"><li>Alignment with FDA on CMC and device plans for Phase 3</li><li>Successfully completed GH001-HV-106 and GH001-HV-109 Phase 1 trials </li><li>Further strengthening of US and EU mebufotenin patent estate</li><li>Phase 2a results in postpartum depression published in <em>The Journal of Clinical Psychiatry</em></li><li>Cash, cash equivalents and marketable securities of $362.7 million as of June 30, 2026</li></ul> <p align="justify">DUBLIN, Aug. 06, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended June 30, 2026, and provided a http://www.streetinsider.com/Press+Releases/GH+Research+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878306.html Thu, 06 Aug 2026 07:00:00 -0400 A.01908724 A.03718595 GHRS O.04906507 O.20988509 O.50288575 http://www.streetinsider.com/Press+Releases/GH+Research+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878306.html <ul type="disc"><li>Alignment with FDA on CMC and device plans for Phase 3</li><li>Successfully completed GH001-HV-106 and GH001-HV-109 Phase 1 trials </li><li>Further strengthening of US and EU mebufotenin patent estate</li><li>Phase 2a results in postpartum depression published in <em>The Journal of Clinical Psychiatry</em></li><li>Cash, cash equivalents and marketable securities of $362.7 million as of June 30, 2026</li></ul> <p align="justify">DUBLIN, Aug. 06, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended June 30, 2026, and provided a http://www.streetinsider.com/Press+Releases/GH+Research+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878306.html Thu, 06 Aug 2026 07:00:00 -0400 A.01908724 A.03718595 GHRS O.04906507 O.20988509 O.50288575 http://www.streetinsider.com/Press+Releases/GH+Research+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878306.html <ul type="disc"><li>Alignment with FDA on CMC and device plans for Phase 3</li><li>Successfully completed GH001-HV-106 and GH001-HV-109 Phase 1 trials </li><li>Further strengthening of US and EU mebufotenin patent estate</li><li>Phase 2a results in postpartum depression published in <em>The Journal of Clinical Psychiatry</em></li><li>Cash, cash equivalents and marketable securities of $362.7 million as of June 30, 2026</li></ul> <p align="justify">DUBLIN, Aug. 06, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended June 30, 2026, and provided a http://www.streetinsider.com/Press+Releases/GH+Research+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878306.html Thu, 06 Aug 2026 07:00:00 -0400 A.01908724 A.03718595 GHRS O.04906507 O.20988509 O.50288575 http://www.streetinsider.com/Press+Releases/GH+Research+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878306.html <ul type="disc"><li>Alignment with FDA on CMC and device plans for Phase 3</li><li>Successfully completed GH001-HV-106 and GH001-HV-109 Phase 1 trials </li><li>Further strengthening of US and EU mebufotenin patent estate</li><li>Phase 2a results in postpartum depression published in <em>The Journal of Clinical Psychiatry</em></li><li>Cash, cash equivalents and marketable securities of $362.7 million as of June 30, 2026</li></ul> <p align="justify">DUBLIN, Aug. 06, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended June 30, 2026, and provided a http://www.streetinsider.com/Press+Releases/GH+Research+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878306.html Thu, 06 Aug 2026 07:00:00 -0400 A.01908724 A.03718595 GHRS O.04906507 O.20988509 O.50288575 http://www.streetinsider.com/Globe+Newswire/GH+Research+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878306.html <ul type="disc"><li>Alignment with FDA on CMC and device plans for Phase 3</li><li>Successfully completed GH001-HV-106 and GH001-HV-109 Phase 1 trials </li><li>Further strengthening of US and EU mebufotenin patent estate</li><li>Phase 2a results in postpartum depression published in <em>The Journal of Clinical Psychiatry</em></li><li>Cash, cash equivalents and marketable securities of $362.7 million as of June 30, 2026</li></ul> <p align="justify">DUBLIN, Aug. 06, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended June 30, 2026, and provided a http://www.streetinsider.com/Globe+Newswire/GH+Research+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878306.html Thu, 06 Aug 2026 07:00:00 -0400 A.01908724 A.03718595 GHRS O.04906507 O.20988509 O.50288575 http://www.streetinsider.com/Globe+Newswire/GH+Research+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878306.html <ul type="disc"><li>Alignment with FDA on CMC and device plans for Phase 3</li><li>Successfully completed GH001-HV-106 and GH001-HV-109 Phase 1 trials </li><li>Further strengthening of US and EU mebufotenin patent estate</li><li>Phase 2a results in postpartum depression published in <em>The Journal of Clinical Psychiatry</em></li><li>Cash, cash equivalents and marketable securities of $362.7 million as of June 30, 2026</li></ul> <p align="justify">DUBLIN, Aug. 06, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended June 30, 2026, and provided a http://www.streetinsider.com/Globe+Newswire/GH+Research+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878306.html Thu, 06 Aug 2026 07:00:00 -0400 A.01908724 A.03718595 GHRS O.04906507 O.20988509 O.50288575 http://www.streetinsider.com/Globe+Newswire/GH+Research+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878306.html <ul type="disc"><li>Alignment with FDA on CMC and device plans for Phase 3</li><li>Successfully completed GH001-HV-106 and GH001-HV-109 Phase 1 trials </li><li>Further strengthening of US and EU mebufotenin patent estate</li><li>Phase 2a results in postpartum depression published in <em>The Journal of Clinical Psychiatry</em></li><li>Cash, cash equivalents and marketable securities of $362.7 million as of June 30, 2026</li></ul> <p align="justify">DUBLIN, Aug. 06, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended June 30, 2026, and provided a http://www.streetinsider.com/Globe+Newswire/GH+Research+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878306.html Thu, 06 Aug 2026 07:00:00 -0400 A.01908724 A.03718595 GHRS O.04906507 O.20988509 O.50288575 http://www.streetinsider.com/Globe+Newswire/GH+Research+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878306.html <ul type="disc"><li>Alignment with FDA on CMC and device plans for Phase 3</li><li>Successfully completed GH001-HV-106 and GH001-HV-109 Phase 1 trials </li><li>Further strengthening of US and EU mebufotenin patent estate</li><li>Phase 2a results in postpartum depression published in <em>The Journal of Clinical Psychiatry</em></li><li>Cash, cash equivalents and marketable securities of $362.7 million as of June 30, 2026</li></ul> <p align="justify">DUBLIN, Aug. 06, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended June 30, 2026, and provided a http://www.streetinsider.com/Globe+Newswire/GH+Research+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878306.html Thu, 06 Aug 2026 07:00:00 -0400 A.01908724 A.03718595 GHRS O.04906507 O.20988509 O.50288575 http://www.streetinsider.com/Globe+Newswire/GH+Research+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878306.html <ul type="disc"><li>Alignment with FDA on CMC and device plans for Phase 3</li><li>Successfully completed GH001-HV-106 and GH001-HV-109 Phase 1 trials </li><li>Further strengthening of US and EU mebufotenin patent estate</li><li>Phase 2a results in postpartum depression published in <em>The Journal of Clinical Psychiatry</em></li><li>Cash, cash equivalents and marketable securities of $362.7 million as of June 30, 2026</li></ul> <p align="justify">DUBLIN, Aug. 06, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended June 30, 2026, and provided a http://www.streetinsider.com/Globe+Newswire/GH+Research+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Business+Update/26878306.html Thu, 06 Aug 2026 07:00:00 -0400 A.01908724 A.03718595 GHRS O.04906507 O.20988509 O.50288575